

# CTAD 2009

Clinical Trials on Alzheimer's Disease

Montpellier '08 | Las Vegas '09 | Toulouse '10 | Barcelona '11

## Clinical Trials on Alzheimer's Disease

<http://www.ctad.fr>

**CTAD  
Las Vegas  
2009**

Clinical Trials



European Alzheimer's Disease Consortium  
Montpellier and Toulouse EADC Centers



**October 29-30, 2009**

**Las Vegas**

Lou Ruvo Center for Brain Health

# on Alzheimer's Disease

*Dear Colleague,*

*It is a great honor to include you as a participant in the second annual Clinical Trials on Alzheimer's Disease [CTaD'09] conference which will take place in Las Vegas, October 29-30, 2009.*

*This year, CTaD'09 is jointly organized by the Montpellier and Toulouse European Alzheimer's Disease Consortium (EADC) Centers, and the Cleveland Clinic Lou Ruvo Center for Brain Health. The objective of the meeting is to create a forum for discussion among key opinion leaders in therapy development for Alzheimer's disease.*

*The topics of discussion will include preliminary or new results concerning drug discovery, clinical trials of new therapies in development, methodological issues relating to disease modifying treatments, outcome measurements, biomarkers validation and health economics.*

*We look forward to seeing you in Las Vegas!*

*Sincerely*

**Zaven KHACHATURIAN, Jacques TOUCHON, Bruno VELLAS**  
Co-Chairs CTaD'09 Las Vegas, Nevada

## Scientific Committee

Paul AISEN (San Diego)  
Kaj BLENNOW (Molndal)  
Maria CARRILLO (Chicago)  
Bruno DUBOIS (Paris)  
Howard FELDMAN (Vancouver)  
Giovanni B. FRISONI (Brescia)  
Lutz FROELICH (Mannheim)  
Serge GAUTHIER (Montreal)  
Ezio GIACOBINI (Geneva)  
Michael GRUNDMANN (San Diego)  
Zaven KHACHATURIAN (Las Vegas)  
Virginia LEE (Philadelphia)  
Jean-Marc ORGOGOZO (Bordeaux)  
Ronald PETERSEN (Rochester)  
Lon SCHNEIDER (Los Angeles)  
Peter SNYDER (Providence)  
Eric SIEMERS (Philadelphia)  
Yaakov STERN (New York)  
Jacques TOUCHON (Montpellier)  
John TROJANOWSKI (Philadelphia)  
Bruno VELLAS (Toulouse)  
Michael W. WEINER (San Francisco)  
Bengt WINBLAD (Stockholm)

## Organizing Committee

Zaven KHACHATURIAN (Las Vegas)  
Jacques TOUCHON (Montpellier)  
Bruno VELLAS (Toulouse)

## Congress secretariat

ANT Congrès  
154 avenue de Lodève - 34070 Montpellier - France  
E-mail : [ctad09@ant-congres.com](mailto:ctad09@ant-congres.com) - Tel : + 33 (0)4 67 10 92 23

## CONTENTS

<b>Program</b> .....	<b>p. 2 - 7</b>
Thursday, October 29 <sup>th</sup> .....	p. 2 - 4
Friday, October 30 <sup>th</sup> .....	p. 5 - 7
<b>Posters</b> .....	<b>p. 8 - 12</b>
<b>CME</b> .....	<b>p. 13</b>
<b>General Information</b> .....	<b>p. 13</b>

## MAJOR SPONSORS



Thursday, October 29 <sup>th</sup>	
8:30 - 10:00 a.m	<b>LECTURES : Pre Dementia Alzheimer's Disease Clinical Trials</b>
10:00 - 10:30 a.m	<i>Coffee Break and poster session</i>
10:30 - 12:00 p.m	<b>LECTURES : Preventive Trials in Alzheimer's Disease</b>
12:00 - 1:00 p.m	<i>Lunch Break</i>
1:00 - 2:00 p.m	<b>ORAL COMMUNICATIONS</b>
2:00 - 3:30 p.m	<b>The German Network on Alzheimer's Trials</b>
3:30 - 4:00 p.m	<i>Coffee Break and poster session</i>
4:00 - 5:45 p.m	<b>ORAL COMMUNICATIONS</b>
6:00 p.m	<b>Guided tour of Cleveland Clinic Lou Ruvo Center for Brain Health</b>

Friday, October 30 <sup>th</sup>	
8:30 - 9:30 a.m	<b>LECTURES : Update on Disease - Modifying Trials</b>
9:30 - 12:15 p.m	<b>PANEL DISCUSSION</b>
12:15 - 1:00 p.m	<i>Lunch Break</i>
1:00 - 2:30 p.m	<b>ORAL COMMUNICATIONS</b>
2:30 - 3:30 p.m	<b>LECTURES : Symptomatic Trials / Disease - Modifying Trials</b>
3:30 - 4:00 p.m	<i>Coffee Break and poster session</i>
4:00 - 5:30 p.m	<b>ORAL COMMUNICATIONS</b>

#### LECTURES : PRE DEMENTIA ALZHEIMER'S DISEASE CLINICAL TRIALS

Chairmen : B. Dubois (Paris), L. Schneider (Los Angeles)

- 8:30 - 9:00 a.m. **L1 Pre Dementia Alzheimer's trials : Overview**  
*P. AISEN, San Diego*
- 9:00 - 9:30 a.m. **L2 Place of biomarkers in Pre Dementia Alzheimer's Trials**  
*M. WEINER, San Francisco*
- 9:30 - 10:00 a.m. **L3 Target Population : MCI vs. Pre Dementia Alzheimer's Disease (New Criteria)**  
*R. PETERSEN, Rochester*
- 10:00 - 10:30 a.m. *Coffee Break and poster session*

#### LECTURES : PREVENTIVE TRIALS IN ALZHEIMER'S DISEASE

Chairmen : M. Weiner (San Francisco), Z. Khachaturian (Las Vegas)

- 10:30 - 11:00 a.m. **L4 The future for preventive trials**  
*L. SCHNEIDER, Los Angeles*
- 11:00 - 11:30 a.m. **L5 Clinical decline in patients who converted to AD in the GUIDAGE study**  
*J. TOUCHON (1), B. VELLAS (2), (1) Montpellier, (2) Toulouse*
- 11:30 - 12:00 p.m. **L6 Multidomain preventive trials : Methodological issues**  
*M. SANO, Philadelphia*
- 12:00 - 1:00 p.m. *Lunch Break*

#### ORAL COMMUNICATIONS - Chairman : L. Frölich (Mannheim)\*

- 1:00 - 1:15 p.m. **O1 NOVEL TRIAL DESIGN FOR PRIMARY PREVENTION TRIALS OF DISEASE-MODIFYING THERAPIES IN AD**  
*D. Darby (1,4), A. Brodtmann (4), M. Woodward (3), P. Maruff (1,2)*  
 (1) CogState Ltd, Melbourne, AUSTRALIA  
 (2) Centre for Neuroscience, University of Melbourne, Parkville, AUSTRALIA  
 (3) Heidelberg Repatriation Hospital, Austin Health, West Heidelberg, AUSTRALIA  
 (4) Florey Neurosciences Institute, Parkville, AUSTRALIA
- 1:15 - 1:30 p.m. **O2 MEMORY CAPACITY TEST (MCT) TO DETECT PRE-SYMPTOMATIC MEMORY IMPAIRMENT AND ALZHEIMER'S DISEASE**  
*H. Buschke, Albert Einstein College of Medicine, Bronx, NY USA*

1:30 - 1:45 p.m    **O3 PREDICTION OF COGNITIVE DECLINE IN HEALTHY OLDER INDIVIDUALS USING TASK-ACTIVATED FMRI, HIPPOCAMPAL VOLUMES, AND APOE STATUS**  
*S.M. Rao, J.L. Woodard, K.A. Nielson, M. Seidenberg, S. Durgerian, P. Antuono, R. Schiffer*  
Cleveland Clinic, Medical College of Wisconsin, Marquette University, Rosalind Franklin University of Medicine and Science, & Wayne State University

1:45 - 2:00 p.m    **O4 HYPERTENSION AS A TREATMENT TARGET FOR PREVENTION OF DEMENTIA: CONSIDERATIONS FOR TRIAL DESIGN BASED ON EXPERIENCE OF THE SCOPE AND PROFESS COGNITIVE SUBSTUDIES**  
*B.K. Saxby (1), K.A. Wesnes (2), G.A. Ford (3)*  
(1) Cognitive Drug Research Ltd., Chicago, USA  
(2) Cognitive Drug Research Ltd., Goring-on-Thames, UK  
(3) Clinical Research Centre, Newcastle University, UK

**2:00 - 3:30 p.m    THE GERMAN COMPETENCE NETWORK ON DEMENTIA – Initial results on Biomarkers and Clinical Trials**

2:00 - 2:20 p.m    **S1 Cohort Characteristics and CSF studies of the German Dementia Competence Network (DCN)**  
*L. FRÖLICH, Mannheim*

2:20 - 2:40 p.m    **S2 Multicenter 1H-MRS studies in Alzheimer’s Disease and MCI in the German Competence Network (DCN)**  
*F. JESSEN, Bonn*

2:40 - 3:00 p.m    **S3 Genetic studies in AD in the German Dementia Competence Network (DCN)**  
*W. MAIER, Bonn*

3:00 - 3:20 p.m    **S4 A multi-center clinical trial on the long-term efficacy of a combination of galantamine and memantine in Alzheimer’s disease**  
*O. PETERS, Berlin*

3:30 - 4:00 p.m    *Coffee Break and poster session*

**ORAL COMMUNICATIONS : Miscellaneous - Chairman : J. Touchon (Montpellier)**

4:00 - 4:15 p.m    **O5 PSYCHOMETRIC PROPERTIES AND CLINICAL SIGNIFICANCE OF THE DEPENDENCE SCALE AS AN OUTCOME IN ALZHEIMER’S DISEASE**  
*K. Wyrwich (1), L. Frank (1), C. Leibman (2), L. Mucha (3), T. McLaughlin (2)*  
(1) United BioSource Corporation, Bethesda, MD, USA  
(2) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA  
(3) Wyeth Research, Collegeville, PA, USA

4:15 - 4:30 p.m

**O6 IDENTIFICATION OF PATIENTS WITH ALZHEIMER'S DISEASE USING MOLECULAR SIGNATURES DERIVED FROM SPLICE VARIANT EXPRESSION PROFILES FROM PERIPHERAL BLOOD**

*P. Fehlbaum-Beurdeley (1), B. Vellas (3), O. Sol (1), W. Zhou (2), A.C. Jarrige-Le Prado (1), M. Calciano (2), P. Gill (2), D. Pallares (1), H. Jordan (2), R. Haddad (1), D. Wu (2), L. Lei (2), R. Einstein (2)*

- (1) ExonHit Therapeutics S.A., 63-65, Bld Masséna, Paris, FRANCE
- (2) ExonHit Therapeutics Inc., 217 Perry Parkway, Gaithersburg, MD, USA
- (3) Gerontopole Toulouse University Hospital, Inserm U 558, FRANCE

4:30 - 4:45 p.m

**O7 IMPAIRMENT OF COGNITION : A HEALTH CARE SERVICES CHALLENGE FOR THE TWENTY-FIRST CENTURY**

*M.D. Schiffer, L. Tara, M.H.A. Estabrooks, A. Loughrin, C. Talerico, B. Randolph*

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA

4:45 - 5:00 p.m

**O8 EVOLUTION OF CLINICAL TRIALS IN DEMENTIA FOR APPROVED AND NOVEL COMPOUNDS : COMPARING 2009 TO 2007**

*T. Alaama (3), M. Smith (2,4,5,6), S. Woolmore-Goodwin (1,3,4), J. Wells (1,2,3,4,5,6), T. Purcell (6), M. Borrie (1,2,3,4,5,6)*

- (1) St. Joseph's Health Care London, Ontario, CANADA
- (2) Lawson Health Research Institute, Ontario, CANADA
- (3) University of Western Ontario, Ontario, CANADA
- (4) Aging Rehabilitation and Geriatric Care, Ontario, CANADA
- (5) Geriatric Clinical Trials Group, Ontario, CANADA
- (6) Consortium of Canadian Centres for Clinical Cognitive Research, Ontario, CANADA

5:00 - 5:15 p.m

**O9 NIA FUNDED ALZHEIMER CENTERS ARE MORE EFFICIENT THAN COMMERCIAL CLINICAL RECRUITMENT SITES FOR PERFORMING SECONDARY PREVENTION TRIALS OF DEMENTIA**

*S.D. Edland (1), J.A. Emond (1), P.S. Aisen (1), R.C. Petersen (2)*

- (1) University of California San Diego, La Jolla, CA, USA
- (2) Mayo Clinic, Rochester, MN, USA

5:15 - 5:30 p.m

**O10 ROLE OF CAREGIVER IN SUBJECT'S COMPLIANCE WITH TREATMENT**

*V. Messick, P. Aisen, R. Raman, J. Edmond, R. Thomas*

Alzheimer's Disease Cooperative Study / University of California San Diego 9500 Gilman Drive 0949 La Jolla, CA, USA

5:30 - 5:45 p.m

**O11 A BI-DIRECTIONAL EFFECT OF NAPROXEN ON THE PATHOGENESIS OF AD: CLINICAL AND BIOLOGICAL EVIDENCE FROM A RANDOMIZED PRIMARY PREVENTION TRIAL**

*J. Breitner*

Seattle, USA

6:00 p.m

**Guided tour of Cleveland Clinic Lou Ruvo Center for Brain Health**

## LECTURES : UPDATE ON DISEASE - MODIFYING TRIALS

Chairmen : B. Vellas (Toulouse), R. Katz (Rockville)

8:30 - 9:00 a.m    **L7 Gamma secretase inhibitors**  
*H. FELDMAN, Vancouver*

9:00 - 9:30 a.m    **L8 Passive immunotherapy**  
*M. GRUNDMAN, San Diego*

## PANEL DISCUSSION

«Approaches for identification of at-risk, but asymptomatic, subjects for longitudinal or prevention studies»

9:30 - 12:15 p.m    **Panel Members** : R. Petersen, D. Barnes, M. Sager, W. Shankle, A. Roses, R. Einstein, P. Snyder, S. Johnson

### Topics of discussion :

1. APOE as predictive markers for age of onset
2. Longitudinal study of adult children of people with AD
3. PET study. Adult children of people with AD
4. ADNI Biomarker experience
5. Early neuropsychological markers
6. Study of risk for AD in older adults
7. Other related issues

10:30 - 11:00 a.m  
*Coffee Break*

12:15 - 1:00 p.m    *Lunch Break*

## ORAL COMMUNICATIONS - Chairman : R. Doody (Houston)

1:00 - 1:15 p.m    **O12 A Novel T Cell Independent Liposomal Vaccine for the Treatment of Patients with Alzheimer's Disease**  
*A. Muhs (1), M. Pihlgren (1), R. Madani (1), V. Giriens (1), D. Hickman(1), M. P. Lopez-Deber (1), A.B. Silva (1), D. Mlaki (1), B. Hutter-Paier (2), I. van der Auwera (3), T. M. Kuendig (4), A. Pfeifer (1)*  
(1) AC Immune SA, PSE Building B, EPFL, 1015 Lausanne, SWITZERLAND  
(2) JSW Life Sciences, Graz, Parkring 12, 8074 Grambach, AUSTRIA  
(3) reMYND, Gaston Geenslaan 1, 3001 Leuven-Heverlee, BELGIUM  
(4) Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, 8091 Zurich, SWITZERLAND

1:15 - 1:30 p.m    **O13 ANALYSIS OF LONGITUDINAL TEST SCORE DATA FROM ALZHEIMER'S DISEASE TRIALS USING REPEATED MEASURES: COMPARING CATEGORICAL VERSUS CONTINUOUS TIME MODELS VIA SIMULATION**  
*G. Crans, K.M. Gregg*  
*Elan Pharmaceuticals, South San Francisco, USA*

1:30 - 1:45 p.m

**O14 A DIRECT SAMPLE SIZE COMPARISON BETWEEN MRI TEMPORAL HORN VOLUMES, CSF AB1-42 AND COGNITIVE DECLINE TO DETECT ALZHEIMER DISEASE PROGRESSION IN ADNI PARTICIPANTS***S.M. Nestor (1,2,4), M. Borrie (3,4), M. Smith (4), J. L. Wells (3,4), R. Bartha (1,2)*

(1) Centre for functional and metabolic mapping, Robarts Research Institute, London, CANADA

(2) The departments of medical biophysics

(3) Medicine, University of Western Ontario, London, CANADA

(4) Division of aging, rehabilitation, and geriatric care, Lawson Health Research Institute, London, CANADA

1:45 - 2:00 p.m

**O15 TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER'S DISEASE***J.W. Ashford (1), M.A. Smith (2), G. Casadesus (2), S.J. Greco (3), J.M. Johnston (3), N. Tezapsidis (3)*

(1) Stanford /va aging clinical research center, vava-hcs, palo alto, CA USA

(2) Case western reserve university, cleveland, OH, USA

(3) Neurotez, inc., bridgewater, NJ, USA

2:00 - 2:15 p.m

**O16 REGIONAL CEREBRAL GLUCOSE METABOLISM PREDICTS DECLINE IN MCI SUBJECTS AND PROVIDES A SENSITIVE BIOMARKER OF DISEASE PROGRESSION***D. Matthews (1), R. Andrews (1), K. Rickert (1), L. Mosconi (2), W. Tsui (2), Y. Li, M. DeLeon (2), and the Alzheimer's Disease Neuroimaging Initiative*

(1) Abiant, Inc., Deerfield, Illinois, USA

(2) New York University Center for Brain Health, New York, USA

**LECTURES : SYMPTOMATIC TRIALS / DISEASE - MODIFYING TRIALS**

Chairmen : P. Aisen (San Diego), C. Sampaio (Lisbonne)

2:30 - 2:50 p.m

**L9 New Insights into Dimebon (latrepirdine) Pharmacology in AD and HD Patients***A. PROTTER, San Francisco*

2:50 - 3:10 p.m

**L10 Update on Dimebon***R. DOODY, Houston*

3:10 - 3:30 p.m

**L11 Safety and exploratory efficacy of EHT 0202 in mild to moderate AD patients : a 3-month, randomized, double-blind, placebo - controlled, phase IIA study***B. VELLAS, P.J. OUSSET, O. SOL, L. DESIRE, M. PANDO, Toulouse*

3:30 - 4:00 p.m

*Coffee Break and poster session*



**ORAL COMMUNICATIONS - Chairmen : M. Sano (Philadelphia)\*, M. Carillo (Chicago)**

- 4:00 - 4:15 p.m** **O17 CITALOPRAM FOR AGITATION IN ALZHEIMER'S DISEASE (CitAD)**  
*I. Zahinoor*, University of Toronto, Queen St W, Toronto Ontario, CANADA
- 4:15 - 4:30 p.m** **O18 REDUCING MEASUREMENT ERROR USING THE MEMORY PERFORMANCE INDEX**  
*W.R. Shankle*, Medical Care Corporation, Irvine, CA, USA
- 4:30 - 4:45 p.m** **O19 HTA-SADD (STUDY OF ANTIDEPRESSANTS FOR DEPRESSION IN DEMENTIA) – PRELIMINARY DATA FROM A MULTICENTRE PRAGMATIC RCT**  
*S. Banerjee on behalf of the HTA-SADD Trial team*  
 Professor of Mental Health and Ageing, PO26, The Institute of Psychiatry, King's College London, London, UK
- 4:45 - 5:00 p.m** **O20 VENTRICULAR ATROPHY AND ITS CLINICAL CORRELATES IN THE IMAGING COHORT FROM THE ADCS MCI DONEPEZIL/VITAMIN E STUDY**  
*L.G. Apostolova (1), S. Babakchian (1), K.S. Hwang (1), A.E. Green (1), D. Zlatev (2), Y. Chou (1), C.R. Jack (3), R.C. Petersen (3), L.J. Thal (4), P.S. Aisen (4), J.L. Cummings (1), A.W. Toga (1), P.M. Thompson (1)*  
 (1) University of California Los Angeles, Los Angeles, CA, USA  
 (2) Northwestern University, Chicago, IL, USA  
 (3) Mayo Clinic, Rochester, MN, USA  
 (4) University of California San Diego, San Diego, CA, USA
- 5:00 - 5:15 p.m** **O21 EFFICACY AND TOLERABILITY OF ONE YEAR MEMANTINE (20 MG) TREATMENT IN BEHAVIORAL VARIANT OF FRONTOTEMPORAL DEMENTIA (BV-FTD): DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL**  
*M. Vercelletto (1), C. Boutoleau-Brettonnière (1), C. Volteau (2), M. Puel (3), S. Auriacombe (4), M. Sarazin (5), B. Michel (6), P. Couratier (7), C. Thomas Anterion (8), A. Gabelle (9), P. Verpillat (10), E. Cerato (11), L. Lacombled (12)*  
 (1) Hôpital R et G Laënnec, C.M.R.R., Centre d'Investigation Clinique, Clinique Neurologique, Boulevard Jacques Monod, Nantes, France  
 (2) Unité d'informatique et de statistiques médicales, DRC CHU de Nantes, Nantes, FRANCE  
 (3) CMRR de Toulouse, Clinique neurologique, Hôpital Purpan, Place du Dr Baylac, Toulouse, FRANCE  
 (4) CMRR de Bordeaux, Clinique neurologique, Hôpital Pellegrin, place A Raba Léon, Bordeaux, FRANCE  
 (5) CMRR Ile de France, Service de Neurologie, Hôpital de la Salpêtrière, 47-48 boulevard de l'Hôpital, Paris, FRANCE  
 (6) Unité de Neurologie, Hôpital Sainte-Marguerite, Marseille, FRANCE  
 (7) CMRR de Limoges, Service de Neurologie, Hôpital Dupuytren, 2 Rue Martin Luther King, Limoges, FRANCE  
 (8) CMRR de Saint Etienne, Clinique Neurologique, Hôpital Bellevue, 25 Boulevard Pasteur, Saint-Etienne, FRANCE  
 (9) CMRR de Montpellier, Montpellier Hôpital Gui de Chauliac 80 Avenue Augustin Fliche, Montpellier, FRANCE  
 (10) NSERM U 679 Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, Paris, FRANCE  
 (11) CHU Nantes DRCI , 5 avenue de l'île Gloriette , Nantes, FRANCE  
 (12) Fédération des Maladies du Système Nerveux, APHP Hôpital de la Salpêtrière, UPMC Paris VI, Pharmacologie, INSERM U 678, Paris, FRANCE
- 5:15 - 5:30 p.m** **O22 DEPRESSION IN ALZHEIMER'S DISEASE-2 (DIADS-2): A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF SERTRALINE FOR DEPRESSION OF ALZHEIMER'S DISEASE**  
*P.B. Rosenber, D. Weintraub, L.T. Drye, B.K. Martin, C. Frangakis, J.E. Mintzer, A.P. Porsteinsson, L.S. Schneider, P.V. Rabins, C.A. Munro, C.L. Meinert, C.G. Lyketos, For the DIADS-2 Research Group*  
 Johns Hopkins University, Baltimore, MD, USA

\*TBC

**P1 DEVELOPMENT OF THE BRIEF DEMENTIA RISK INDEX: A SIMPLE TOOL TO IDENTIFY HIGH-RISK ELDERS FOR DEMENTIA PREVENTION TRIALS**

*D.E. Barnes (1), K.E. Covinsky (1), R.A. Whitmer (2), L.H. Kuller (3), O.L. Lopez (1), K. Yaffe (1)*

(1) University of California, San Francisco and San Francisco va medical center, San Francisco, CA, USA

(2) Kaiser permanente division of research, Oakland, CA, USA

(3) University of Pittsburgh, Pittsburgh, PA, USA

**P2 THE MENTAL ACTIVITY AND EXERCISE (MAX) TRIAL**

*D.E. Barnes, K. Yaffe, et al.*

University of California, San Francisco and San Francisco va medical center, San Francisco, CA, USA

**P3 ALZHEIMER DISEASE - MALNUTRITION AND NUTRITIONAL SUPPORT – COMPARATIVE AND INTERVENTION STUDY**

*M. Navratilova (1), J. Jarkovsky (2), A. Vasku (3), M. Hamrova (4), B. Leonard (5), L. Sobotka (6)*

(1) Psychiatric Clinic, dpt. of Psychiatry, Masaryk University Hospital, Brno, CZECH REPUBLIC

(2) Institute of Biostatistics and Analyses

(3) Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, CZECH REPUBLIC

(4) Dpt. of Clinical Nutrition, Masaryk University Hospital, Brno, CZECH REPUBLIC

(5) Pharmacology Dpt., National University of Ireland, Galway, IRELAND

(6) Gerontometabolic Clinic, Charles University Hospital, Hradec Kralove, CZECH REPUBLIC

**P4 CAN EVENT RELATED POTENTIAL (ERP) PREDICT THE PROGRESSION OF MCI? A PROSPECTIVE STUDY**

*K. Bennys (1), N. Reza (2), G. Rondouin (1), J. Touchon (1)*

(1) Memory Research Resource Center for Alzheimer's Disease, Department of Neurology, University Hospital of Montpellier, FRANCE

(2) University of Virginia School of Medicine, USA

**P5 ART AND DEMENTIA : FIRST EUROPEAN STUDY OF THE ARTISTICS PRODUCTIONS AMONG DEGENERATIVE DEMENTIA**

*L. Bernard-Bourzeix, S. Durieux, A. Druet Cabanac, P. Couratier, T. Dantoine, J.P. Clément*

CMRR Limousin, CHU-CHS, Limoges, FRANCE

**P6 EPIGENETIC FACTORS IN AGING PROCESS: IMPLICATIONS IN GEROPROTECTORS DESIGN**

*N. Cucu (1), G. Anton (2), G.L. Radu (3), I. Turcu (4), L. Spiru (4)*

(1) University of Bucharest, Epigenetics Lab, Bucharest, ROMANIA

(2) Stefan Nicolau Institute of Virology, Bucharest, ROMANIA

(3) National Institute of research and development in biological sciences, Bucharest, ROMANIA

(4) Ana Aslan International Academy of Aging, Bucharest, ROMANIA

**P7 GENDER CORRELATES OF MILD COGNITIVE IMPAIRMENT (MCI) TO ALZHEIMER'S DISEASE (AD) CONVERSION**

*L. Spiru, I. Ioancio, C. Nuta, M. Blaciotti*

Ana Aslan International Academy of Aging, Bucharest, ROMANIA

**P8 NATURE AND NURTURE IN NORMAL BRAIN AGING AND IN ALZHEIMER'S DISEASE**

*L. Spiru, I. Turcu*

Ana Aslan International Academy of Aging, Bucharest, ROMANIA

- P9 HAVE WE SUFFICIENT INSIGHTS TO RECONSIDER PROCAINE AS A POTENT MOLECULE IN ALZHEIMER'S DISEASE?**  
*L. Turcu, L. Spiru*  
 Ana Aslan International Academy of Aging, Bucharest, ROMANIA
- P10 SITE-SPECIFIC SCREENING AND ENROLLMENT RATES**  
*A. Gamst*  
 University of California, San Diego, La Jolla, CA, USA
- P11 SHAPE-INVARIANT MODELING OF COGNITIVE DECLINE**  
*A. Gamst*  
 University of California, San Diego, La Jolla, CA, USA
- P12 MEASUREMENT BURSTS IMPROVE PRECISION OF ESTIMATED RATE OF COGNITIVE DECLINE**  
*J.R. Steinerman, M.J. Sliwinski, H. Buschke, W. Ramratan, C.H. Hall, R.B. Lipton*  
 Albert Einstein College of Medicine, New York, USA
- P13 ACCELERATED HIPPOCAMPAL ATROPHY IN SUBJECTS WITH MATERNAL HISTORY OF ALZHEIMER'S DISEASE**  
*L.G. Apostolova, J. Andrawis, K.S. Hwang, A.E. Green, J.H. Morra, J. Kotlerman, A. Ramirez, D. Elashoff, J.L. Cummings, P. M. Thompson*  
 University of California, Los Angeles, CA, USA
- P14 EFFECTS OF MUSIC THERAPY ON ANXIETY AND DEPRESSION IN PATIENTS WITH ALZHEIMER'S DISEASE: A RANDOMISED CONTROLLED TRIAL**  
*S. Guétin (1,2,4), F. Portet (1), M.C. Picot (3), C. Pommier (1,2), M. Messaoudi (1), L. Djabelkir (1), E. Lecourt (4), J. Touchon (1,2)*  
 (1) Service de Neurologie, Centre Mémoire de Ressources et de Recherches (CMRR); Inserm U888, CHRU Montpellier, Montpellier, FRANCE  
 (2) Association de Musicothérapie Applications et Recherches Cliniques (AMARC), Paris, FRANCE  
 (3) Département d'Information Médicale, CHRU Arnaud de Villeneuve, Montpellier, FRANCE  
 (4) Laboratoire de Psychologie Clinique et Psychopathologie (LCPL) EA 4056; Université Paris-Descartes, Paris, FRANCE
- P15 COGNITIVE EFFECTS OF PARKINSONIAN SIGNS IN OLDER PEOPLE IN A COMMUNITY-BASED STUDY**  
*M.H. Park (1), C. Han (2)*  
 (1) Departments of Neurology, Korea University College of Medicine, Ansan, REPUBLIC OF KOREA  
 (2) Departments of Psychiatry, Korea University College of Medicine, Ansan, REPUBLIC OF KOREA
- P16 EFFECT OF DONEPEZIL ON STRUCTURAL MRI AND CLINICAL MARKERS IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: a Randomized, placebo-controlled trial : THE HIPPOCAMPUS STUDY**  
*B. Dubois (1), M. Sarazin (1), S. Lehericy (3), M. Chupin (2), I. Tonelli (4), L. Garnero (2), D. Dormont (2), "Donepezil Hippocampus Study Group"*  
 (1) INSERM-UPMC UMRS 610, Federation of Neurology, AP HP, Salpêtrière Hospital, University Paris 6, Paris, FRANCE  
 INSERM U610 unit, Federation of Neurology, Salpêtrière hospital, Paris, FRANCE  
 (2) Cognitive Neuroscience and Brain Imaging Laboratory, CNRS UPR640, Salpêtrière hospital, Paris, FRANCE  
 (3) INSERM U610 unit, and CENIR, Neuro-imaging Unit, Salpêtrière hospital, Paris, FRANCE  
 (4) Eisai SAS, Paris, FRANCE

- P17** **EVP-6124, AN ALPHA-7 NICOTINIC AGONIST, PRODUCES PRO-COGNITIVE EFFECTS AND IS WELL TOLERATED IN ALZHEIMER'S DISEASE PATIENTS ON STABLE ACETYLCHOLINESTERASE INHIBITOR THERAPY**  
*J. Apter (1), B. Safirstein (2), D. Hassman (3), S. Thein (4), P. Maruff (5), J. Harrison (5), M. Gawryl (6), D. Hilt (6)*  
 (1) Global Medical Institutes, Princeton, NJ, USA  
 (2) MD Clinical, Hallandale Beach FL, USA  
 (3) Comprehensive Clinical Research, Berlin, NJ, USA  
 (4) Pacific Research Network, Inc. San Diego, CA, USA  
 (5) CogState Ltd, Melbourne, AUSTRALIA  
 (6) EnVivo Pharmaceuticals, Watertown, MA, USA
- P18** **THE DIFFERENTIAL DIAGNOSIS OF DEMENTIA – A STILL CHALLENGING FIELD**  
*L. Spiru, I. Turcu, F. Halici*  
 Ana Aslan International Academy of Aging, Bucharest, ROMANIA
- P19** **MORBI-MORTALITY PREDICTIVE WEIGHT LOSS THRESHOLD AT PATIENTS WITH ALZHEIMER'S DISEASE FOLLOWED IN AMBULATORY**  
*O. Guérin (1), S. Etesse-Winckel (1), P. Robert (1), C. Cantet (2), B. Vellas (2)*  
 (1) Department of gerontology and geriatrics, CMRR, CHU Nice, FRANCE  
 (2) Inserm U558, Department of internal medicine and geriatrics, CHU Toulouse, FRANCE
- P20** **ORAL MASITINIB IN PATIENTS SUFFERING FROM MILD-TO-MODERATE ALZHEIMER'S DISEASE**  
*F. Piette (1), P. Cherubin (2), T.H. Bader (2), A. Moussy (2), O. Hermine (3)*  
 (1) Hôpital Charles Foix, Ivry-sur-Seine, FRANCE  
 (2) AB Science, Paris, FRANCE  
 (3) Hôpital Necker, Paris, FRANCE
- P21** **THE NTB DEMONSTRATES HIGH TEST-RETEST AND INTERRATER RELIABILITY**  
*D. Rentz (1), E. Eng (1), J. Harrison (2), G. Crans (3), R. Motalli (3), T. McLaughlin (3), E. Liu (3), R. Black (4), M. Grundman (3),*  
*for the ELN-AIP-901 Study Investigator Group*  
 (1) Harvard Medical School, Boston, MA, USA  
 (2) Imperial College, London, UK  
 (3) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA  
 (4) Wyeth Pharmaceuticals, Collegeville, PA, USA.
- P22** **DESIGNING EARLY (PRE-DEMENTIA) ALZHEIMER'S DISEASE TRIALS : LINEAR MIXED MODELS VERSUS TIME TO CONVERSION**  
*M. Donohue, A. Gamst, P. Aisen*  
 University of California San Diego, San Diego, CA, USA
- P23** **ASSOCIATIONS BETWEEN TEMPORAL HORN VOLUMES DERIVED FROM MRI, CSF AB1-42 CONCENTRATIONS AND COGNITIVE DECLINE IN ADNI PARTICIPANTS**  
*S.M. Nestor (1,2,4), M. Borrie (3,4), M. Smith (4), J.L. Wells (3,4), R. Bartha (1,2)*  
 (1) Centre for functional and metabolic mapping, Robarts Research Institute, London, CANADA  
 (2) The departments of medical biophysics  
 (3) Medicine, University of Western Ontario, London, CANADA  
 (4) Division of aging, rehabilitation, and geriatric care, Lawson Health Research Institute, London, CANADA

- P24 WHY EXERCISER TRAINING IS AN EFFICACIOS INTERVENTION FOR DEMENTIA ?**  
*P.C. Heyn*  
 School of medicine, University of Colorado Denver, Denver, Colorado, USA
- P25 PHYSICAL ACTIVITY IS ASSOCIATED WITH ENHANCED SEMANTIC MEMORY ACTIVATION IN OLDER APOE-ε4 CARRIERS**  
*S.M. Rao, J.C. Smith, K.A. Nielson, J.L. Woodard, M. Seidenberg, S. Durgerian, P. Antuono, A. Butts, N. Hantke, R. Schiffer*  
 Cleveland Clinic, Medical College of Wisconsin, University of Wisconsin-Milwaukee, Marquette University, Rosalind Franklin University of Medicine and Science, and Wayne State University, USA
- P26 MEASUREMENT OF EPISODIC MEMORY USING WORD-BASED TASKS IN DIFFERENT LANGUAGES : VALIDATION FROM MULTICENTER CLINICAL TRIALS**  
*B.K. Saxby (1), R.E. Stacey (2), A.C. Embleton (2), N.A. Meinel (2), K.A. Wesnes (2)*  
 (1) Cognitive Drug Research Ltd., Chicago, USA  
 (2) Cognitive Drug Research Ltd., Goring-on-Thames, USA
- P27 MEASUREMENT OF APATHY AND NEUROPSYCHIATRIC SYMPTOMS IN CLINICAL TRIALS**  
*P.H. Robert , E. Mullin, R. David, P. Malléa*  
 Memory Center (CMRR) & Center for innovation in Health care (CIU-S), Nice, FRANCE
- P28 MOLECULAR STATUS OF PLASMA FIBRONECTIN AS AN ADDITIONAL BIOMARKER FOR ASSESSMENT OF ALZHEIMER'S DEMENTIA RISK**  
*J. Leszekb (2), A. Lemańska-Pereka (1), D. Krzyżanowska-Gołąba (1), J. Radzikb (2), I. Katnik-Prastowskaa(1)*  
 (1) Department of Chemistry and Immunochemistry, Wrocław University of Medicine, Bujwida 44a, 50-345 Wrocław, POLAND  
 (2) Department, and Clinic of Psychiatry, Wrocław University of Medicine, Pasteura 10, 51-348 Wrocław, POLAND
- P29 COMPUTATIONAL APPROACHES FOR IDENTIFICATION OF NEW TARGETS AND PRE-CLINICAL VALIDATION**  
*O.M. Mitrasinovic*  
 Stanford University, CA, USA
- P30 PROGNOSIS OF MILD COGNITIVE DEFICIT ABOUT THE EVOLUTION TO ALZHEIMER'S DISEASE**  
*J. Villalobos, D. Sotomayor, G. Hernández, G. Orduz*  
 Neurology Medical Center, University Of Sinu, Monteria, Cordoba, COLOMBIA
- P31 PKR IS A TARGET FOR NEUROPROTECTION IN ALZHEIMER'S DISEASE**  
*J. Hugon, C. Paquet, F. Mouton liger, A. Bose, F. Gray*  
 Memory Center ( CMRR Paris Nord IdF) Hôpital Lariboisière Fernand Widal, Paris, Inserm UMR U839 Paris, FRANCE
- P32 DIFFERENCES IN B-AMYLOID POOL IN BLOOD DISCRIMINATE BETWEEN AMNESIC MILD COGNITIVE IMPAIRMENT PATIENTS (AMCI) AND HEALTHY CONTROLS (HC)**  
*M. Sarasa (1), P. Pesini (1), M. Boada (2), P. Martínez-Lage (2), L. Tàrraga (2), I. Monleón (1), V. Pérez-Grijalba (1), I. San-José (1), J. Porcel-Carbonell (3), A. Gutiérrez-Blanco (3)*  
 (1) Araclon Biotech, Zaragoza, SPAIN  
 (2) Fundació ACE, Barcelona, SPAIN  
 (3) Biometria Clínica, Barcelona, SPAIN

**P33 DENUTRITION IN THE ELDERLY SUFFERING FROM CANCER AND COGNITIVE IMPAIRMENT ADMITTED IN LIMOGES ONCOGERIATRIC UNIT**

*T. Dantoin* (1,3), *A. Tchalla* (1), *I. Saulnier* (1,3), *F. Lachal* (1), *A. Labrousse* (1,3), *M.A. Picat* (1,3), *C. Gayot* (1,3), *J. Martin* (2,3), *N. Tubiana-Mathieu* (2,3)

- (1) Pôle de Gérontologie, CHU de Limoges, Limoges, FRANCE
- (2) Service d'Oncologie médicale, CHU de Limoges, Limoges, FRANCE
- (3) Unité Pilote d'Oncogériatrie, CHU de Limoges, Limoges, FRANCE

**P34 EVALUATION OF THE B-AMYLOID POOL IN BLOOD BY ELISA SANDWICH IS MEANINGFUL AND RELIABLE**

*M. Sarasa* (1), *P. Pesini* (1), *I. Monleón* (1), *V. Pérez-Grijalba* (1), *I. San-José* (1), *M. Boada* (2), *P. Martínez-Lage* (2), *L. Tárrega* (2), *J. Porcel-Carbonell* (3), *A. Gutiérrez-Blanco* (3)

- (1) Araclon Biotech, Zaragoza, SPAIN
- (2) Fundació ACE, Barcelona, SPAIN
- (3) Biometría Clínica, Barcelona, SPAIN

**P35 THE UNEXPECTED CAPACITY OF MELANIN TO DISSOCIATE THE WATER MOLECULE EXPLAINS THE COMMON HISTOLOGICAL FINDINGS BETWEEN ALZHEIMER'S DISEASE AND AGE-RELATED MACULAR DISEASE**

*A. Solís-Herrera*, *M. Del Carmen Arias Esparza*, *R.I. Solís-Arias*, *P.E. Solís-Arias*, *M.P. Solís-Arias*  
Human Photosynthesis Study Center, S.C., Life's Sciences Division, MEXICO

**P36 DEVELOPMENT OF HOMOLOGOUS MARKERS TO MONITOR DISEASE PROGRESSION IN ANIMAL MODELS AND HUMANS**

*G.B. Frisoni* (1), *D. Bartres-Faz* (2), *C. Babiloni* (3), *F. Aujard* (4), *Y. Lamberty* (5), *R. Bordet* (6), *P. Payoux* (7), *J. Atack* (8), *E. Schenker* (9), *M.J. O'Neill* (10), *P. Verwaerde* (11), *G. Forloni* (12), *O. Della-Pasqua* (13), *D. Wille* (13), *J. Georges* (14), *O. Blin* (15), *E.A. Irving* (13)

- (1) IRCCS Fatebenefratelli, Brescia, ITALY
- (2) University of Barcelona, SPAIN
- (3) University of Foggia, ITALY
- (4) CNRS, FRANCE
- (5) UCB Pharma
- (6) University of Lille, FRANCE
- (7) INSERM, FRANCE
- (8) Janssen Pharmaceutica
- (9) Institut de Recherche Servier
- (10) Eli Lilly
- (11) AlzProtect
- (12) Mario Negri Institute, ITALY
- (13) GlaxoSmithKline R&D, and the Pharma-Cog Consortium
- (14) Alzheimer Europe
- (15) University of Marseille, FRANCE

Posters will be displayed in La Tache room (where coffee breaks and lunches are being held) and listed by abstract number.

- Posters set-up : Thursday, October 29<sup>th</sup> from 8.00 to 9.30 a.m
- Posters take-out : Friday, October 30<sup>th</sup> from 4.00 to 5.30 p.m

(A technician will be available to help you with your poster display)

## C.M.E

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Nevada School of Medicine and the Clinical Trials on Alzheimer's Disease consortium. The University of Nevada School of Medicine is accredited by the ACCME to provide medical education to physicians.

The University of Nevada School of Medicine designates this educational activity for a maximum of 13.5 AMA PRA Category 1 Credits(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### Participant Sign-in and verification of Attendance

Participants are required to sign-in at the beginning of the activity and return a completed Activity Evaluation/Verification of Attendance form to the registration desk at the conclusion of the activity. Only those individuals who sign in and return an evaluation form will receive a certificate of attendance.

### Replacement Certificates of Attendance

In the event a certificate of attendance is lost, please contact the Office of Continuing Medical Education for a replacement.

University of Nevada School of Medicine  
Office of Continuing Medical Education  
Reno, Nevada 89503

(775) 784-1983  
(775) 784-4207 – fax  
ocme@med.unr.edu

### Disclosure Policy

As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, the University of Nevada School of Medicine requires that anyone in a position to control or influence the content of a continuing medical education activity disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented.

## GENERAL INFORMATION



### Congress Venue

Wynn Las Vegas Hotel  
3131 Las Vegas Blvd. South  
Las Vegas NV 89101

Phone : (702) 770-7000

[www.wynnlasvegas.com](http://www.wynnlasvegas.com)

**Nevada Geriatric Education Center**, a joint program of the University of Nevada School of Medicine and the Sanford Center for Aging, provided support through funds from the Bureau of Health Professions (BHP), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS) under grant number D31HP08800 and title of Geriatric Education Centers for a total award of \$648,000.

*The information or content and conclusions of this program are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by the BHP, HRSA, DHHS or the U.S. Government.*

# Let's meet next year in Toulouse, FRANCE

# CTAD 2010

Montpellier '08 | Las Vegas '09 | Toulouse '10 | Barcelona '11

## Clinical Trials on Alzheimer's Disease

Clinical Trials

<http://www.ctad.fr>

**CTAD  
Toulouse  
2010**



European Alzheimer's Disease Consortium  
Montpellier and Toulouse EADC Centers



**November 3-5, 2010**

Toulouse

Hôtel-Dieu Saint Jacques